BTHS is an X-linked cardiac and skeletal mitochondrial myopathy caused by mutation of the gene encoding tafazzin 1 , an acyltransferase responsible for normal acylation of cardiolipin, the major phospholipid of the mitochondrial inner membrane 2 (Supplementary Fig. 1 ; data tables for supplementary data are available as Supplementary Data Sets). Cardiolipin abnormalities also occur in ischemic heart disease and aging and have been implicated in the cardiac dysfunction characteristic of these conditions 3 . The mechanisms that lead from abnormal cardiolipin biogenesis to cardiomyopathy are not well understood. Here, we combined patient-derived iPSCs, genome editing, modified RNA (modRNA) 4 and bioengineered microchips that simulate myocardial tissue ('heart-on-chip') 5 to replicate the pathophysiology of BTHS cardiomyopathy in tissue constructs. Using these approaches, we identified mitochondrial functional abnormalities caused by TAZ mutation and cardiolipin deficiency. We show that TAZ mutation is necessary and sufficient to disrupt sarcomere assembly and contractile stress generation and that these functional abnormalities are not due to global ATP depletion. Furthermore, we show that the BTHS cardiomyopathic phenotype is readily reversed by re-introduction of wild-type (WT) TAZ or by suppression of excessive reactive oxygen species (ROS) produced by BTHS mitochondria. These results provide new insights into the links between mitochondrial function, sarcomere assembly and muscle contractile activity and suggest new therapeutic strategies for BTHS.
These iPSC lines had normal karyotype and met pluripotency criteria (Supplementary Fig. 2 ; all cell lines in this study are summarized in Supplementary Table 1) . As controls, we used three normal iPSC lines, generated by retroviral (WT1 and WT2) or modRNA (WT3) reprogramming (Supplementary Table 1 ). We carried out the experiments presented below multiple times and using multiple cell lines with consistent results; we provide representative data in the accompanying figures and supplementary information and an overview of the data collected in Supplementary Table 2 .
We differentiated the iPSCs into iPSC-CMs using an established protocol 9 ( Supplementary Fig. 3a-c) , and then used magnetic cell sorting for the cardiomyocyte surface marker vascular cell adhesion molecule-1 (VCAM-1) 10, 11 to obtain preparations containing ~80% iPSC-CMs ( Supplementary Fig. 3d-f ). On replating, the enriched myocytes formed sheets of cardiomyocytes ( Supplementary Fig. 3g ) that beat spontaneously (Supplementary Movie 1) .
BTHS is characterized by depletion of mature cardiolipin and accumulation of an immature form, monolysocardiolipin ( Supplementary  Fig. 1 ) 12, 13 . Phospholipid profiles of BTHS iPSC-CMs, measured by mass spectrometry, confirmed that abnormal cardiolipin processing was recapitulated in BTHS iPSC-CMs (Fig. 1a) . The monolysocardiolipin-to-cardiolipin ratio in BTHS iPSC-CMs exceeded 0.3, the clinically used diagnostic threshold for BTHS 13 (Fig. 1a,b) . Thus, BTHS iPSC-CMs exhibited impaired cardiolipin biogenesis that matched what is observed clinically in patients with BTHS.
We assessed mitochondrial morphology and function in BTHS iPSC-CMs. FACS analysis showed that BTHS iPSC-CMs had mitochondrial numbers similar to those of control iPSC-CMs and that BTHS iPSC-CM mitochondria were smaller than control mitochondria ( Supplementary Fig. 4a,b) . This smaller size was associated with greater fragmentation of BTHS iPSC-CM mitochondria compared to the more highly networked mitochondria of controls ( Supplementary Fig. 4c ). To assess BTHS mitochondrial function, we cultured iPSC-CMs in galactose-based medium, which has limited ability to support ATP production via glycolysis 14 . Under these conditions, BTHS iPSC-CM ATP levels were significantly lower than those of wild-type iPSC-CMs (Fig. 1c) . Consistent with cellular energy deprivation, the activated form of AMP-dependent kinase was markedly upregulated in BTHS iPSC-CMs ( Supplementary  Fig. 5a ). Next, we used an extracellular flux analyzer to probe mitochondrial function (the approach and the terms used are described in Supplementary Fig. 5b,c) . BTHS iPSC-CMs unexpectedly exhibited an elevated basal oxygen consumption rate, which was a result of both increased F 1 F 0 ATP synthase oxygen consumption and increased 'H + leak' (Fig. 1d,e and Supplementary Fig. 5d ). In the context of reduced basal ATP levels, these data pointed to inefficient F 1 F 0 ATP synthase activity, which we confirmed by selective complex immunocapture followed by measurement of F 1 F 0 ATP synthase quantity and activity (Supplementary Fig. 5e ). We also measured respiratory capacity, which reflects maximal electron transport chain activity, and found that it was severely impaired in BTHS iPSC-CMs (Fig. 1d,e) .
Collectively, these data demonstrate that TAZ deficiency and consequent cardiolipin abnormalities reduce peak electron transport chain function and decrease ATP generation efficiency by lowering F 1 F 0 ATP synthase-specific activity. The metabolic abnormalities of BTHS iPSC-CMs were not evident in BTHS primary fibroblasts or iPSCs ( Supplementary Fig. 5f,g ), consistent with the muscle-selective phenotype of patients with BTHS.
Cardiomyocytes are capable of producing ATP through both glycolysis and oxidative phosphorylation. We hypothesized that glucose, an energy source that supports both glycolysis and oxidative phosphorylation, would normalize ATP levels. Indeed, glucose induced glycolysis and triggered a metabolic shift away from oxidative phosphorylation in both BTHS and control iPSC-CMs ( Supplementary  Fig. 5h,i ). This metabolic shift normalized BTHS iPSC-CM ATP levels and basal oxygen consumption rate ( Fig. 1f and Supplementary  Fig. 5j ). However, glucose culture did not correct the markedly depressed respiratory capacity of BTHS iPSC-CMs ( Supplementary  Fig. 5j ). These observations indicate that glucose restores basal ATP levels through increased glycolysis but does not correct underlying mitochondrial defects in the electron transport chain.
TAZ mutation causes BTHS iPSC-CM phenotypes
Because iPSCs derived from patients with BTHS and control iPSCs have numerous genetic differences other than TAZ mutation, we took three independent approaches to further establish the causative role of TAZ mutation in abnormal cardiolipin biogenesis and mitochondrial function. First, we used adenoviral delivery of TAZspecific short hairpin RNAs (shRNAs) to deplete TAZ in neonatal rat ventricular cardiomyocytes (NRVMs) by over 80% at 72 h after infection ( Supplementary Fig. 6a ). At this time point, cardiolipin profiles in NRVMs with TAZ knockdown were already highly abnormal ( Supplementary Fig. 6b ), indicating rapid turnover of TAZ and mature cardiolipin. As in BTHS iPSC-CMs, TAZ deficiency in NRVMs grown in galactose reduced ATP levels, activated AMPdependent kinase ( Supplementary Fig. 6c,d ) and caused comparable abnormalities in mitochondrial function (Supplementary Fig. 6e ). Electron microscopy did not reveal alterations in mitochondrial morphology or number in this short-term TAZ depletion experiment ( Supplementary Fig. 6f ), suggesting that mitochondrial functional abnormalities are not contingent upon the mitochondrial structural abnormalities observed in patients with BTHS. Second, we used modRNA technology 4, 7, 15 in which 5-methylcytidine and pseudouridine are substituted for cytidine and pseudouridine, respectively, to efficiently re-introduce TAZ into BTHS iPSC-CMs.
Cardiomyocytes, including iPSC-CMs, are refractory to standard transfection methods. modRNA has minimal toxicity 4, 7, 15 and efficiently transfects cardiomyocytes 16 (Supplementary Fig. 7 ). TAZ modRNA likewise transfected iPSC-CMs, and TAZ protein localized to mitochondria (Fig. 2a) . TAZ modRNA restored cardiolipin biogenesis and normalized basal mitochondrial function in BTHS iPSC-CMs, although maximal respiratory capacity was rescued incompletely (Fig. 2b-e) . These results indicate that TAZ mutation is necessary to confer the BTHS mitochondrial phenotype and that this phenotype is rapidly reversed upon TAZ restoration.
Third, we used Cas9-mediated scarless genome editing 17 to mutate TAZ in the control human iPSC line PGP1-iPSC, yielding three iPSC lines that are isogenic except for the sequence of TAZ exon 6 (Supplementary Table 1 and Fig. 3a-c ; the Online Methods and Supplementary Fig. 8 contain details on the construction and validation of these iPSC lines). PGP1-TAZ c.517delG contains the TAZ frameshift mutation from the BTH-H line (1-nt deletion), and PGP1-TAZ c.517ins contains a distinct frameshift mutation at the same site (14-nt insertion; Fig. 3a-c) . PGP1-TAZ WT is a control line that was handled identically to the PGP1-TAZ c.517delG and PGP1-TAZ c.517ins lines but contains a WT TAZ sequence. iPSC-CMs derived from these isogenic TAZ mutant lines fully recapitulated the cardiolipin, mitochondrial and ATP deficits that we observed in patient-derived iPSC and NRVM TAZ knockdown models (Fig. 3d-g and Supplementary Table 2) . Together, these data indicate that TAZ mutation alone is sufficient to cause these defects in an otherwise unaffected genetic background.
Abnormal sarcomerogenesis in BTHS iPSC-CMs
Mitochondria regulate cardiomyocyte maturation 18 , a hallmark of which is assembly of organized arrays of sarcomeres. We noticed that BTH-H iPSC-CMs grown on an unpatterned gelatin substrate assembled sarcomeres more irregularly than did control iPSC-CMs. To compare sarcomere architecture more precisely, we engineered iPSC-CM shape by seeding the cells on micropatterned fibronectin rectangles designed to mimic the dimensions of human adult cardiomyocytes 19 , with length/width ratios of approximately 7:1 (95 m × 13 m). To quantify the global regularity of sarcomere arrangement, we developed an unbiased metric to score images of patterned iPSC-CMs immunostained for the sarcomere protein -actinin. This metric, which we named sarcomere organization, is based on the regularity of sarcomere spacing, as determined from two-dimensional (2D) Fourier spectra of the sarcomere immunostains ( Supplementary Fig. 9a-c and Online Methods). Whereas sarcomeres in control iPSC-CMs extended serially along the entire length of the cell, sarcomeres in BTH-H iPSC-CMs were intermittent and sparse (Fig. 4a) . Treatment with TAZ modRNA restored sarcomere regularity (Fig. 4a) . These differences were reflected in the sarcomere organization metric, which was lower in BTH-H iPSCCMs than in controls and was increased by TAZ modRNA treatment (Fig. 4a) . Although glucose culture normalized ATP levels to a degree comparable to that achieved with TAZ modRNA, glucose culture did not rescue sarcomere formation (Fig. 4a) . These defects in sarcomere assembly were recapitulated in genome-edited PGP1-TAZ c.517delG and PGP1-TAZ c.517ins iPSC-CMs but were not observed in isogenic PGP1-TAZ WT controls (Fig. 4b) , confirming the causative role of the BTH-H exon 6 frameshift TAZ mutation. These data suggest that sarcomerogenesis is sensitive to mitochondrial function independently of whole-cell ATP levels.
Notably, BTH-C iPSC-CMs exhibited sarcomere organization that was not significantly different from that of controls (Fig. 4c) . This phenotypic heterogeneity between BTH-H and BTH-C iPSC-CMs may be due to the nature of the specific TAZ mutations or to other variables between the cell lines. Further use of genome-edited cell lines will be necessary to better understand genotype-phenotype relationships in this disease.
Heart-on-chip model of BTHS myopathy and its genetic rescue Because patients with BTHS often develop cardiomyopathy, we asked whether we could replicate the contractile pathophysiology of BTHS in an in vitro model of engineered myocardium and demonstrate the efficacy of TAZ modRNA treatment in this model. Toward this goal, we used our heart-on-chip assay 5, 20 to quantitatively measure the contractility of engineered myocardial tissue assembled from BTHS or control iPSC-CMs. iPSC-CMs selected via magnetic-activated cell sorting (MACS) were seeded onto thin elastomers micropatterned with fibronectin lines and supported by glass coverslips 21, 22 . Over a 5-d culture period, the iPSC-CMs self-organized into laminar anisotropic myocardium. Staining for sarcomeric -actinin in control iPSC-CM-containing tissue revealed both aligned sarcomeres and fibrous structures indicative of the relatively immature phenotype of iPSC-CMs (Fig. 5a) , findings that are similar to previous observations in immature primary rat cardiac myocytes 23 . Like individual iPSC-CMs seeded on fibronectin rectangles, engineered BTHS iPSC-CM-containing tissue exhibited impaired sarcomere assembly compared to controls (Supplementary Fig. 10a ). We then peeled precut muscular thin film (MTF) tissue constructs from the glass substrate, allowing them to contract and curl away from the plane of the coverslip ( Fig. 5a and Supplementary Movie 2) . We used movies of contracting MTFs to calculate radii of curvature, from which we calculated the diastolic and peak systolic stresses using a modification of Stoney's equation 5 between diastolic and peak systolic stress (Fig. 5a) . During electrical field stimulation, control iPSC-CM MTFs contracted rhythmically at frequencies ranging from 1 to 5 Hz (Fig. 5b, Supplementary  Fig. 10b and Supplementary Movie 2). BTH-H iPSC-CM tissues developed significantly lower twitch and peak systolic stress compared to controls over the same stimulation frequency range, indicating that BTHS engineered myocardial tissue recapitulates the BTHS myopathic phenotype. Next, we asked whether these engineered myocardial tissue constructs effectively model disease correction. Treatment of BTH-H iPSC-CMs (Fig. 5b, Supplementary Fig. 10 and Supplementary Movie 2) with TAZ modRNA for 5 d restored contractile function of MTF tissue constructs to levels comparable to those of controls, further confirming that this myopathic phenotype is reversible and due to TAZ mutation.
We assessed the contribution of whole-cell ATP to BTHS contractile dysfunction by culturing engineered iPSC-CM MTF constructs in glucose-containing medium, which we showed above increases ATP in BTHS iPSC-CMs to a level comparable to that seen with TAZ modRNA treatment. In contrast to TAZ modRNA rescue, glucose culture alone did not restore BTH-H iPSC-CM MTF force generation at any tested stimulation frequency (Fig. 5b, Supplementary Fig. 10b ,c and Supplementary Movie 3). Although local pools of mitochondrially produced ATP might theoretically be required for iPSC-CM force generation, such a mechanism is unlikely because inhibition of mitochondrial ATP production with oligomycin in control iPSC-CM MTFs did not alter their contractile strength ( Supplementary Fig. 11) ; this finding is consistent with the immature and highly glycolytic properties of iPSCCMs. Together, these data show that BTH-H iPSC-CMs have a severe defect in contractility that occurs independently of ATP depletion.
This result is consistent with anectodal data we obtained from a patient with BTHS that showed preserved cardiac high-energy phosphate levels in the setting of impaired heart function ( Supplementary Fig. 12 ). Taken together, these data suggest that contractile dysfunction in BTHS occurs despite normal myocardial energy stores.
We next reproduced the findings from patient-derived BTHS iPSCCMs in the isogenic, genome-edited cells. Contractile function of mock-manipulated PGP1-TAZ WT iPSC-CM myocardial constructs was equivalent to that of constructs derived from the parental PGP1 cell line, whereas constructs derived from TAZ mutation-containing iPSC-CMs (PGP1-TAZ c.517delG or PGP1-TAZ c.517ins ) caused severe loss of contractile stress generation (Fig. 5c, Supplementary Fig. 10c and Supplementary Movie 4). Re-introduction of TAZ by modRNA restored contractility to mutant tissue constructs (Fig. 5c,  Supplementary Fig. 10c and Supplementary Movie 4) . Thus, in both patient-derived cells and cells with an isogenic background, TAZ deficiency causes contractile dysfunction.
BTH-C myocardial tissue constructs also showed poor contractile function, which was reflected in their markedly reduced beating activity (Supplementary Movie 2) and severely depressed twitch stress (Fig. 5d) . Systolic stress generation was also reduced significantly in BTH-C myocardial tissue constructs compared to controls (Fig. 5d) . However, their peak systolic (and diastolic) stresses were substantially higher than in their BTH-H counterparts (Fig. 5b,d) , perhaps reflecting the difference in sarcomere assembly that we observed between these TAZ genotypes (Fig. 4a,c) .
Assessment of potential therapies using BTHS iPSC-CMs
We used BTHS iPSC-CMs to measure the effect of three proposed interventions for BTHS: bromoenol lactone, an inhibitor of mitochondrial phospholipase A 2 , which catabolizes mature cardiolipin 25 ; linoleic acid (LA), an essential unsaturated fatty acid precursor of mature cardiolipin 26 ; and arginine plus cysteine, amino acids that are frequently deficient in patients with BTHS 27 . LA and bromoenol lactone partially corrected the monolysocardiolipin/cardiolipin ratio in BTHS iPSC-CMs, whereas arginine plus cysteine had no effect (Fig. 6a) . Treatment of galactose-cultured BTHS iPSC-CMs with LA or arginine plus cysteine increased ATP to levels comparable to those seen in control iPSC-CMs or BTHS iPSC-CMs rescued with TAZ modRNA, whereas bromoenol lactone had no significant effect (Fig. 6b) . LA, but not arginine plus cysteine, also normalized the basal and F 1 F 0 ATP synthase oxygen consumption rates of BTHS iPSC-CMs but had little effect on maximal mitochondrial respiratory capacity ( Fig. 6c and Supplementary Fig. 13 ). Thus, of the three tested treatments, LA was most effective at correcting the metabolic phenotype of BTHS iPSC-CMs.
Because LA had a positive effect in each of these metabolic assays, we asked whether LA supplementation could mitigate the sarcomere organization and contractile defects of BTHS iPSC-CMs. LA improved the sarcomere organization of BTH-H iPSC-CMs (Fig. 6d) . No statistically significant improvement was noted in BTH-C iPSC-CMs, whose sarcomeric organization was not significantly different from that of controls. In both BTH-H and BTH-C myocardial tissue constructs, LA dramatically increased twitch stress to nearly normal levels (Fig. 6e) . This was reflected in an obvious effect of LA on rhythmic beating of the BTHS myocardial MTF constructs (Supplementary Movie 5). Thus, LA rescued the contractile deficits of BTHS iPSC-CMs.
In addition to potentially enhancing alternative pathways of cardiolipin synthesis, LA might also influence BTHS iPSC-CM phenotype by scavenging ROS. An extensive literature implicates high levels of ROS in ischemic and hypertensive heart failure, in part through effects on sarcomere assembly and function 28 . Uncoupling of the electron transport chain and elevated mitochondrial membrane potential, both of which were observed in BTHS iPSC-CMs ( Fig. 1 and Supplementary Fig. 14a-d) , promote mitochondrial ROS production. Indeed, we found that mitochondrial ROS production was markedly increased in BTHS iPSC-CMs, as assessed by measurement of 4-hydroxynonenal, a product of lipid peroxidation, or as assessed by MitoSOX, a mitochondrially targeted probe with ROS-enhanced fluorescence ( Supplementary Fig. 14e ). 4-Hydroxynonenal levels were suppressed to near baseline by LA (Fig. 6f) . To distinguish antioxidant from cardiolipin-precursor mechanisms of LA action, we tested the mitochondrially targeted and structurally unrelated antioxidant mitoTEMPO. Like LA, mitoTEMPO suppressed excessive ROS in BTHS iPSC-CMs (Fig. 6g) .
Having confirmed that mitoTEMPO effectively suppresses excessive mitochondrial ROS in BTHS iPSC-CMs, we next determined whether mitoTEMPO treatment could improve sarcomere organization and force generation. Indeed, mitoTEMPO treatment normalized the sarcomere organization and contractility of BTHS iPSC-CMs (Fig. 6h,i These data indicate that iPSC-CMs and heart-on-chip technology enable effective in vitro testing of candidate therapeutic agents. Furthermore, these data link impaired sarcomerogenesis and weak force generation in BTHS iPSC-CMs to excessive ROS production.
DISCUSSION
Patient-derived iPSCs have considerable potential to enhance our understanding of human disease and enable therapeutic screening on a personalized basis. However, several barriers still hinder adoption of iPSC disease models academically, clinically and commercially. One obstacle to wider use of iPSC disease models has been the genetic and epigenetic variation between cell lines, which introduces confounding variables that can be difficult to control. We show that Cas9-mediated genome editing is a useful strategy to isolate a mutation of interest and show that it is sufficient to cause a disease phenotype. Gene replacement using modRNA technology is another highly portable approach that demonstrates the acute requirement of a gene mutation for a disease phenotype within a given cell line.
Another major impediment to the use of iPSCs to study human disease pathogenesis has been the lack of in vitro models that reproduce disease pathophysiology. With respect to cardiomyopathies, modeling the contractile function of iPSC-CMs at the level of myocardial tissue has been challenging, and prior iPSC-based models of cardiomyopathy have focused on measurements of single-cell contractile function 29, 30 . Here, we assembled anisotropic laminar myocardial tissue constructs from iPSC-CMs and used these to document impaired contractile stress generation in BTHS. Furthermore, we used this approach to model phenotypic rescue at the tissue level by gene replacement and small-molecule treatments.
Our metabolic and functional analysis of human BTHS cardiomyocytes elucidated mitochondrial functional impairment caused by mature cardiolipin depletion. Our data show that the contractile deficit of BTHS iPSC-CMs is not a result of global cellular energy depletion. Rather, we show that TAZ deficiency in BTHS impairs sarcomere assembly and contractile stress generation. It is likely that sarcomere assembly is only one of several factors that lead to reduced twitch stress in BTHS iPSC-CMs, as the extent of sarcomere disarray did not necessarily correlate with impairment of twitch stress across our assays. We found that TAZ deficiency in BTHS caused markedly increased ROS production and that suppression of ROS normalized the metabolic, sarcomerogenesis and contractile phenotypes of BTHS iPSCCMs. These data indicate that excessive ROS production contributes to sarcomere disarray and reduced contractile stress generation in BTHS iPSC-CMs. ROS has been implicated in cardiomyocyte differentiation, sarcomerogenesis and contractility 18, 28 . Our data indicate that ROS scavenging may be beneficial for patients with BTHS and suggest that this strategy should be further validated using in vivo models. Our findings may be relevant to more common conditions such as ischemia and aging, as mature cardiolipin depletion and elevated ROS production also occur in these states 3 .
METHODS
Methods and any associated references are available in the online version of the paper.
ONLINE METHODS
iPSC derivation and culture. Low-passage skin fibroblasts were obtained from skin biopsies from two unrelated patients with BTHS with informed consent under protocols approved by the Boston Children's Hospital Institutional Review Board. WT1 control iPSCs were derived from BJ fibroblasts (Stemgent), and WT2 and WT3 iPSCs were described previously 7, 8, 31 . The BTH-H iPSC line was established by retroviral delivery of four reprogramming factors (OCT4, SOX2, KLF4 and Myc) 6 . The BTH-C iPSC line was established by modRNA reprogramming as described 7 . Several iPSC clones with embryonic stem cell morphology and with positive vital staining for TRA-1-81 or TRA-1-60 staining 32 
iPSC cardiac differentiation and iPSC-CM culture. Cardiomyocyte differentiation was induced as previously reported 9 , with minor modifications. Cells were detached by 3-to 5-min incubation with Versene (Invitrogen) and seeded onto Matrigel-coated plates at a density of 10,000 cells/cm 2 in mouse embryonic fibroblast conditioned medium (MEF-CM) plus 4 ng/mL human basic fibroblast growth factor (Stemgent) for 2-3 d before induction. Cells were covered with Matrigel (1:60 dilution) on the day before induction. To induce cardiac differentiation, we replaced MEF-CM with RPMI+B27 medium (RPMI-1640, 2 mM l-glutamine, ×1 B27 supplement without insulin) supplemented with 100 ng/mL of Activin A (R&D Systems) for 24 h, followed by 10 ng/mL human bone morphogenetic protein-4 (R&D) and 10 ng/mL human basic fibroblast growth factor for 4 d without culture medium changes. The culture medium was subsequently replaced with RPMI+B27 supplemented with 100 ng/mL of DKK1 (R&D) for 2 d. At day 7, the culture medium was changed to RPMI+B27 without supplementary cytokines; culture medium was refreshed every 1-2 d. Leibovitz L-15 medium was substituted for RPMI for galactose-containing culture medium. For iPSC-CM enrichment, differentiation cultures were dissociated with Accumax (Innovative Cell Technologies). Dissociated cells were stained with anti-VCAM-1 antibody (Supplementary Table 3 contains antibody information) conjugated with allophycocyanin (APC) and enriched by magnetically activated cell sorting (MACS) using anti-APC microbeads (Miltenyi Biotec). For MACS validation, sorted cells were fixed and stained with TNNT2 primary and Alexa-488-conjugated secondary antibody. Data were analyzed with FlowJo (Treestar) software. For MitoTEMPO treatment, iPSC-CMs were purified by VCAM-1 MACS and reseeded on muscle thin films at 1 million cells per well of a six-well plate (described below). The cells were treated with MitoTEMPO (Sigma) at a final concentration of 5 M for 5 d. Linoleic acid (Sigma) was freshly prepared for each use from sealed ampules. It was dissolved in ethanol and used at a final concentration of 50 M.
Cas9-mediated genome editing. Details of our modified Cas9-mediated genome editing strategy will be published separately. In brief, we constructed a piggyBac transposon that expresses the reverse tetracycline activator and a human codon-optimized Cas9 under the control of a tet response element. Stable transfection of PGP1-iPSCs (Coriell Institute for Medical Research) with this engineered transposon yielded PGP1-iPSC-hCas9 cells. We subsequently designed guide RNA and donor oligonucleotides (Fig. 3a-c, Supplementary  Fig. 8 and Supplementary Table 4 ) to introduce the BTH-H TAZ mutation into exon 6. After transient doxycycline administration and transfection with guide RNA and donor oligonucleotides, we screened individual clones by Sanger sequencing. We selected an unmodified clone, a clone containing the BTH-H mutation (resulting from homology-directed repair) and a clone containing an insertion resulting from nonhomologous end joining. Transient transfection with a plasmid expressing piggyBac transposase subsequently led to removal of the Cas9-containing transposon.
TAZ sequencing. TAZ sequencing was performed using previously described primers 33 Cardiac 31 P nuclear magnetic resonance. Cardiac 31 P nuclear magnetic resonance imaging was performed as described 34 with informed consent under a protocol approved by the Institutional Review Board of the Children's Hospital of Philadelphia. High-energy phosphate stores were estimated from the phosphocreatine peak area, normalized to the peak area from the phosphate of ATP 34 .
Mitochondrial function assays.
For mitochondrial function assays, 60,000 sorted cells were seeded in 0.1% gelatin-coated Seahorse assay wells in alpha MEM (Invitrogen) with 10% FBS. They were then changed to L-15 medium supplemented with 1x B27 supplement without insulin for 5-7 d. Oxygen consumption rate (OCR) was measured using a Seahorses Biosciences XF24 extracellular flux analyzer using the Cell Mito Stress Kit (Seahorses Biosciences) and normalized to total protein, determined using the BCA protein assay (Thermo Scientific). OCR was expressed as pmol/min/10 g protein. Based on changes OCR after addition of FCCP, oligomycin or antimycin/rotenone, we calculated the mitochondrial function metrics described in Supplementary Figure 5b, 
Mitochondrial isolation and FACS analysis.
Mitochondrial isolation and FACS analysis were performed to measure mitochondrial size, number, membrane potential and production of ROS. Mitochondrial isolation and FACS were performed based on described protocols 35 . In brief, iPSC-CMs were digested to single cells by Versene, and mitochondria were isolated using the Mitochondria Isolation Kit (Thermo Scientific). 20 million iPSC-CMs were pelleted by centrifugation at 850g for 2 min. The pellet was resuspended in 800 l of mitochondria isolation reagent A with protease inhibitor. The suspension was vortexed at medium speed for 5 s and then incubated on ice for exactly 2 min. Next, 10 l mitochondria isolation reagent B was added and vortexed at maximum speed for 5 s. After 5 min of incubation on ice with vortexing at maximum speed every minute, 800 l mitochondria isolation reagent C with protease inhibitor was added. The tube was centrifuged at 700g for 10 min at 4 °C. The supernatant was transferred to a new microcentrifuge tube and centrifuged at 3,000g for 15 min. The supernatant was discarded and 500 l mitochondria isolation reagent C was added to the pellet. The sample was then centrifuged at 12,000g for 5 min. The mitochondrial pellet was resuspended in 200 l FACS buffer (Stemcell Technologies). Either MitoSOX (5 M; Life Technologies) or TMRM (100 nM; Life Technologies) and MitoTracker green (50 nM; Life Technologies) were incubated with mitochondria at room temperature for 30 min. The sample was then analyzed by flow cytometry. Data were analyzed by using FlowJo software. Fluorescence intensity is reported in arbitrary units based on the readout of the FACS instrument.
NRVM culture. NRVMs were isolated from postnatal day 1 rat heart ventricles by collagenase digestion using the Neomyts isolation kit (Cellutron). Control and TAZ shRNA viruses were constructed as described previously 36 using sequences provided in Supplementary Table 4 . NRVM isolation was performed according to protocols approved by the Boston Children's Hospital Institutional Care and Use Committee.
Imaging and gene expression analysis. Immunostaining for marker expression was performed using antibodies listed in Supplementary Table 3 . Samples were fixed in 4% paraformaldehyde and permeabilized with 0.05% Triton X-100. Imaging was performed on an Olympus FV1000 or Zeiss LSM 5 LIVE confocal microscope. Quantitative RT-PCR was performed from total RNA using primers listed in Supplementary Table 4 . SYBR green chemistry was used for real-time PCR detection on an ABI 7500 instrument. Western blotting was performed using antibodies specified in Supplementary Table 3 .
Mitochondria were labeled using BacMam 2.0 mitochondria-RFP (Invitrogen), in which a baculovirus vector delivers RFP tagged with the mitochondrial localization sequence of pyruvate dehydrogenase E1 subunit .
Electron microscopy was performed on a Tecnai G Spirit BioTWIN instrument. At least ten randomly selected fields containing cardiomyocytes were imaged per sample.
Analysis of lipids.
Cardiolipin and monolysocardiolipin were analyzed by high-performance liquid chromatography-mass spectroscopy as described previously 37 . The monolysocardiolipin/cardiolipin ratio was calculated from these mass spectrum data. Lipid peroxidation product 4-HNE was measured by ELISA (Cell Biolabs).
Modified RNA synthesis and delivery. The iPSC reprogramming cDNA templates were obtained from Addgene 7 . The TAZ modRNA cDNA template was expressed from pcDNA3.3-TOPO-T7-5 UTR-cMyc-3 UTR, which contains the T7 promoter and optimized 5 and 3 untranslated regions (Addgene plasmid 26818) 7 . The vector was modified to place unique AscI and NheI restriction sites between the 5 and 3 untranslated regions. Full-length human TAZ cDNA corresponding to RefSeq NM_000116 with a 5 Flag tag was cloned into the modified vector.
To synthesize modRNA, the untranslated regions and open reading frames were PCR amplified using a poly(A)-tailed primer. 1.6 g of purified PCR product was transcribed in a 40 l reaction system using the MEGAscript T7 kit (Ambion, Austin, TX) and a custom ribonucleoside cocktail from Allele Biotechnology (No. ABP-PP-NTPMIX) containing pseudouridine-5 -triphosphate, methylcytidine-5 -triphosphate, GTP, ATP and ARCA (Cap Analog). Reactions were incubated 6 h at 37 °C. After DNase treatment, RNA was purified with Ambion MEGAclear spin columns and then treated with Antarctic Phosphatase (New England BioLabs) for 30 min at 37 °C. Treated RNA was repurified and adjusted to a 100 ng/mL working concentration with Tris-EDTA (pH 7.0).
Modified mRNA transfection experiments were performed with RNAiMAX (Invitrogen). Transfection medium was supplemented with 200 ng/ml B18R interferon inhibitor (eBioscience). After 4 h, the transfection medium was replaced with fresh culture medium containing 200 ng/ml B18R.
Microcontact printing.
Standard soft lithography techniques were used to fabricate polydimethylsiloxane (PDMS) stamps for microcontact printing (Sylgard 184, Dow Corning Midland, MI), as previously described 38, 39 . Briefly, a silicon wafer was spin-coated with SU-8 3005 (MicroChem Corp., Newton, MA) and selectively exposed to ultraviolet light using a photomask. After being developed, the wafer was used as a template for PDMS stamps. For the singlecell studies, we used stamps with 95 m × 13 m rectangles. For the muscular thin film (MTF) studies, we used stamps with 15-m wide lines separated by 2 m.
To measure sarcomere organization in single-cell studies, glass coverslips (18 mm in diameter) were spin-coated with PDMS and cured. PDMS stamps were coated with 50 g/mL fibronectin (BD Biosciences, San Jose, CA) for 1 h, dried and inverted onto the coverslips after treatment in a UVO cleaner (Jelight Company, Irvine, CA). Stamps were removed, and the coverslips were incubated in 1% Pluronic F-127 acid (BASF, Mount Olive, NJ) for at least 5 min before being rinsed with PBS and stored at 4 °C. MACS-purified iPSC-CMs were plated on microfabricated fibronectin islands for 5 d and transfected daily with the indicated modRNA.
Quantitation of sarcomere organization. For quantitation of sarcomere organization of iPSC-CMs plated on fibronectin islands, images of single myocytes stained for sarcomeric -actinin were analyzed using custom-designed software in ImageJ (NIH, Bethesda, MD) and MATLAB (Mathworks, Natick, MA). Images were preprocessed to highlight the filamentous structure of the cytoskeleton using a tubeness operator 40 , which replaces each pixel in the image with the largest nonpositive eigenvalue of the image Hessian matrix. To calculate the ability of single cells to spread across the microcontact-printed islands, the convex hulls 41 of sarcomeric -actinin-and fibronectin-binarized immunostains were obtained and used to calculate cell projected surface area.
The regularity of spacing between the cytoskeletal elements that stained positive for sarcomeric -actinin (Supplementary Fig. 9a,b) was assessed by first considering the magnitude of the oscillatory portion of the 2D Fourier transform of preprocessed and binarized immunostains (Supplementary Fig. 9a,b) :
(1) (1) To fully automate the analysis and remove any user bias 42 , 512 radial profiles of the 2D Fourier transform were summed to obtain a one-dimensional representation -( ) n -of the 2D spectrum (blue dots in Supplementary Fig. 9a,b ) that was further normalized so that the total area under the curve would be 1. A least-square minimization was performed to find the vector of parameters for which the function ( , ) best fits the N experimental data points:
The functional form of ( , ) was composed by an aperiodic component, representing the effect of poorly developed cytoskeletal structures (equation (4); black curves, Supplementary Fig. 9 ) and a periodic component (equation (5), red curves, Supplementary Fig. 9 ) relating to periodically spaced Z-discs:
In agreement with Fourier analysis, the periodic component was approximated with a series of Gaussian peaks localized at integer multiples of the spatial frequency ( 0 = 1/r 0 ) associated with the sarcomere length (r 0 ~2 m).
The area under the peaks of the periodic component was taken as a metric of structural organization and named sarcomere organization, as the organization increases as more sarcomeric -actinin-positive elements become localized in the Z-discs at a distance ~r 0 . We normalized all sarcomere organization values to the maximum value observed across all single cells before plotting.
MTF fabrication and experiments. MTF chips were fabricated on 22 mm × 22 mm glass coverslips that were 0.13-0.16 mm thick (Ted Pella, Redding, CA) 20, 21 . Coverslips were covered with low-adhesion Scotch tape (3M, St. Paul, MN), and two rectangles with dimensions of 18 mm × 5.8 mm spaced 8.6 mm apart (distance from center to center) were cut into the tape with a 10.6-m-wavelength CO 2 laser prototyping system (VersaLaser 2.0, 10W, Universal Laser Systems, Scottsdale, AZ). Cut rectangles were peeled using a sharp tweezer, and then a 10% (w/v) solution of poly(N-isopropylacrylamide) (PIPAAm, Polysciences, Warrington, PA) in 99% butanol was spin-coated at 6,000 r.p.m. for 1 min. This allowed for PIPAAm deposition within bare-glass regions. The rest of the tape was then peeled off and PDMS mixed at 10:1 ratio of base to curing agent was spin-coated at 4,000 r.p.m. for 1 min. PDMS-coated chips were placed in a 65 °C oven for at least 8 h to allow complete curing of the elastomer. The Young's modulus in compression of cured Sylgard 184 mixed in the ratio of 10:1 base/curing agent was determined to be 1.52 0.05 MPa (n = 18 samples, mean s.d.) using an Instron 3342 mechanical apparatus (Instron, Norwick, MA). In the final step, two rows of cantilever outlines were cut into the elastomer within the PIPAAm rectangular regions such that the final cantilevers were 5 mm × 2 mm or 3 mm × 2 mm, spaced 2.5 mm apart (distance from center to center) 20 . For each batch of films, the thickness of the elastomer was measured using a profilometer (Dektak 6M, Veeco Instruments, Plainview, NY) and found to be in the range of 11.4-13.4 m.
MACS-purified iPSC-CMs were seeded on MTF constructs at a density of 1 × 10 5 per cm 2 and allowed to develop for 5 d, with daily transfection with modRNA as indicated. For contraction assays, MTF constructs were transferred to 37 °C Tyorde's buffer solution (1.8 mM CaCl 2 , 5 mM HEPES, 1 mM MgCl 2 , 5.4 mM KCl, 135 mM NaCl, 0.33 mM NaH 2 PO 4 and either 5 mM glucose or galactose depending on the experimental conditions, pH 7.4) and placed on the stage of a Zeiss Discovery V8 Stereo Microscope at room temperature. Tweezers were used to manually peel each thin film away from the glass coverslip as the PIPAAm layer dissolved because of the slight drop in temperature. When (2) (2) (3) (3) (4) (4) (5) (5) all films were peeled, the constructs were rewarmed to 37 °C and paced with platinum field-stimulation electrodes. Films were paced at 1, 2, 3, 4 and 5 Hz, and their movement was recorded from above at 100 frames per second. Films paced at 2 Hz were used for statistical comparison because this frequency was closest to the spontaneous beat rate.
MTF stress quantitation.
The longitudinal planar projections of contracting MTFs were automatically detected using custom ImageJ (NIH, Bethesda, MD) software and used to calculate the radius of curvature of each film using custom MATLAB software (Mathworks, Natick, MA), as previously described 5 . The stress of the cell layer was determined from the radius of curvature using a modified form of Stoney's equation:
where cell is the stress of the cell layer, E, v and t s are the Young's modulus, Poisson's ratio and thickness of the PDMS film, respectively, R is the MTF radius of curvature and t c is the thickness of the cell layer. Equation (6) can be readily derived based on the theory of the cylindrical bending of thin plates 43 and the static equilibrium of the force and torque of plate bending 44 . The plate modulus E/(1 − v 2 ) instead of the biaxial modulus E/(1 − v), appears in equation (6) because the anisotropic contraction of the cell layer bends the PDMS film into a cylindrical shape instead of a bowl-like shape. The factor (1 + t c /t s ) −1 is a correction to the standard Stoney's equation 44 when the thickness of the cell layer approaches that of the PDMS layer. We previously used a more comprehensive model 24 to calculate not only the stress in the film but also the shortening of the muscle layer. For the MTFs used in this paper, the stresses calculated by these two methods are almost identical, so we chose to adopt the simpler analytical form of the modified Stoney's equation.
Statistical analyses.
Results are reported as mean s.e.m. Unless otherwise indicated, we used unpaired Student's t-tests with unequal variances. Stress values failed the Shapiro-Wilkinson test for normality and were thus statistically (6) (6) compared using Kruskal-Wallis one-way ANOVA on ranks and Dunn's method for pairwise comparisons. Tests with a P value less than 0.05 were considered statistically significant. No statistical method was used to predetermine sample size. The experiments were not randomized. The sarcomere organization and MTF assays were performed blinded to allocation during outcome assessment. Other experiments were not blinded to allocation during experiments and outcome assessment.
Introduction
Designer site-specific nucleases such as TALENs [1, 2] and CRISPR/Cas9 [3, 4] have opened the door for rapid genome engineering. By introducing targeted double strand breaks into a genome, these nucleases stimulate endogenous repair mechanisms. One repair mechanism is non-homologous end joining (NHEJ), in which a double strand break is repaired by joining the DNA ends. NHEJ repair is error-prone and causes insertions and deletions (indels) around the DNA break point. In the presence of a donor DNA template with homology to the region of the DNA break, homology-directed repair (HDR) occurs. By placing sequence variations or exogenous DNA fragments between homology arms, the HDR mechanism can be leveraged to program specific insertions, deletions, or base changes at a target locus.
With the aid of designer site-specific nucleases, targeted genome modification can be achieved with sufficient efficiency that the desired modifications can be recovered without use of positive selection cassettes [3] [4] [5] . This is an important advance over more traditional gene targeting strategies, since it obviates the need to remove the selection cassette. Selection cassette removal requires additional handling and moreover typically leaves residual sequences. When first described using the CRISPR/Cas9 system, ''scarless'' genome editing efficiency was in the 1-4% range [4, 5] . At this efficiency, a large number of clones need to be screened to obtain a single targeted clone. Screening strategies involving selective amplification of cell pools containing targeted clones have been described that overcome this limitation [6] . However, increasing the frequency of targeted clone recovery represents an alternative and more direct approach to optimize scarless genome editing.
Here, we report a series of experiments that investigate several parameters that influence the efficiency of scarless genome editing using the CRISPR/Cas9 system. Key parameters include (a) optimization of transfection efficiency; (b) enrichment for transfected cells; (c) integration of downstream genotyping into the design of the targeting strategy; and (d) optimizing the design of the donor DNA template. Through these improvements, we increased the efficiency of genome editing: we routinely achieved 30-60% efficiency for homozygous targeted gene knockout through NHEJ, and 4% efficiency for addition of a GFP epitope tag onto endogenous genes.
Materials and Methods

Plasmids and oligonucleotides
The pCas-9-GFP, pCas9D10A-GFP, and gRNA cloning vectors were obtained from Addgene. The traditional MEF2C FlagBio target vector containing the FlagBio ORF and Frt-NeoFrt cassette flanked by 1 kb and 4 kb homolog arms was made by recombineering [7] . The dsDNA donor with 50 bp homolog arms on each side was made by PCR, using primers harboring 50 bp homology sequences. The Oct4-GFP donor with 200 bp homolog arms was made using the Gibson assembly technique [8] using a kit from New England Biolabs, with pCR-Blunt II-TOPO vector (Life Technologies) as backbone. 
MLL2-qPCR-F tgttcccggctttaccacttt
MLL2-qPCR-R ggctccatgatagtgatgccc
CHD7-qPCR-F gacccagggatgatgagtctt
CHD7-qPCR-R atggggttcacggggttttc
GAPDH-qPCR-F acagtccatgccatcactgcc
GAPDH-qPCR-R gcctgcttcaccaccttcttg gRNAs:
primers for genotyping:
SAP130-DONOR tcatcccatgctactgctgtgaccacttcaaatatcccagttggcaagtgttggacatgtcgcacaaaagcctttgaggaatttgcaggc
50 bp-homolog FlagBio donor for Mef2c:
50 bp-homolog GFP donor for Mef2c:
50 bp-homolog GFP donor for OCT4:
OCT4-GFP-F cctttccctctgttcccgtcactgctctgggctctcccatgcattcaaacgtgagcaagggcgaggagct
OCT4-GFP-R gtctacctcccttgccttggctcacagcatccccagggagggctggtgccttacttgtacagctcgtcca
Gibson assembly to make 200-bp homolog donor for OCT4:
Oligonucleotides were synthesized by Integrated DNA Technologies. Primer sequences are indicated in Table 1 . gRNAs were designed using the CRISPR design tool (crispr.mit.edu) [9] .
Cell Culture
Mouse J1 ESCs (ATCC) were cultured on MEF-coated gelatinized plates at 37 in 5% CO 2 in ES medium. ES medium contained Dulbecco's modified Eagle's medium (DMEM) (high glucose, Life Techologies) supplemented with 15% ES-qualified fetal bovine serum (Invitrogen), LIF (Millipore), GlutaMAX, 2-mercaptoethanol, MEM non-essential amino acids, and penicillin/ streptomycin.
Transfection
Traditional electroporation was done using a Gene Pulser electroporator (BioRad) at 250 V, 500 uF. Nucleofection was performed using the mouse ESC nucleofection kit (VPH-1001; Amaxa). Lipofectamine 3000 (Life Technologies, L3000008) and Xfect (Clontech) were used according to manufactures' protocols. To enrich for transfected cells, GFP FACS was performed 48 hours after transfection. Alternatively, pgk-puromycin plasmid was co-transfected with Cas9 in a 2:3 ratio. After 48 hours, cells were selected in 1.5 mg/ml puromycin for 48 hours.
Genotyping and surveyor assay
Mouse ESCs were digested overnight in lysis buffer (10 mM Tris-Hcl 7.5, 10 mM EDTA, 10 mM NaCl, 1% SDS, and 1 mg/ ml proteinase K). Genomic DNA was purified by ethanol precipitation. PCR primers flanking the target regions were designed by Primer 3 software. For Surveyor nuclease assay, 800 ng PCR products were melted and annealed in 1X Taq buffer for heteroduplex formation. The hybrid DNA was treated with 1 ml enhancer S and 1 ml nuclease S according to manufacture's protocol. The reaction products were analyzed on 4-20% Novex TBE polyacrylamide gels (Life Technologies), and visualized by Sybr Gold nucleic acid staining (Life Technologies, S-11494).
Gene Expression
RNA was purified using the RNeasy mini kit (Qiagen, 74104). cDNA synthesis was performed using Superscript III first-strand synthesis system for RT-PCR (Life Technologies, 18080-051). Quantitatative PCR was performed with Sybr Green chemistry, using GAPDH as the endogenous control. Primer sequences are indicated in Table 1 .
Results
The CRISPR system offers unprecedented genome editing capability. Ideally, such genome-editing would be scarless (i.e. without need for a selection cassette) yet highly efficient. A major factor that reduces the fraction of genome-edited clones in the absence of positive selectable markers incorporated into the modified allele is transfection efficiency. To deliver CRISPR components more efficiently into mouse ES cells (mESCs), we tested four different transfection methods: traditional electroporation; nucleofection; and two different, recently introduced liposomal agents (Xfect and Lipofectamine 3000 (LF3000)). We transfected Cas9-GFP expression plasmids to mESCs, and analyzed the percentage of GFP positive cells by fluorescenceactivated cell sorting (FACS; Figure 1 ). Nucleofection and LF3000 performed the best or second best in three replicate experiments that measured the fraction of transfected cells and the mean fluorescence intensity ( Figure 1B) . In subsequent experiments, we used either nucleofection or LF3000 since these gave the highest transfection efficiency for the pCas9-GFP plasmid, the active reagent in these genome editing experiments.
Optimization of CRISPR-mediated gene knockout
We established a system in which we could easily monitor the efficiency of CRISPR gene knockout. Our lab previously described a mESC line in which a CAG-promoter driven L10a-GFP fusion protein was knocked into the Rosa26 locus [10] . These heterozygous L10a-GFP mESCs robustly express GFP (Fig. 2A) . We co-transfected these cells with hCas9 and a gRNA directed against GFP (Fig. 2B) . Subsequent FACS analysis showed that 21.1% of cells were GFP 2 after transfection (Fig. 2C) , compared to 0.9% in cells not treated with hCas9.
Expression of hCas9 and a target-specific gRNA causes gene knockout by introducing a double strand break, which is repaired by non-homologous end joining (NHEJ). In the presence of the appropriate DNA donor, the double strand break also stimulates homology-directed repair (HDR). We hypothesized that programming a DNA donor template with a stop codon would increase the efficiency of generating knockouts through the HDR pathway. We tested this hypothesis on the L10a-GFP locus. We found that hCas9+gRNA alone (NHEJ) yielded 20.760.9% GFP -cells, while hCas9+gRNA+DNA donor (both NHEJ and HR) yielded 34.962.3% GFP 2 cells (P,0.05; Fig. 2D ). Although the knockout efficiency varied based on the transfection efficiency, the rank order was consistent between trials (Fig. 2D) . Thus, adding a donor oligo with stop codon increased KO efficiency compared to hCas9 plus gRNA alone.
Next, we considered whether the number of gRNAs influenced Cas9 knockout efficiency. We compared GFP knockout in L10a-GFP mESCs treated with one gRNA (#3 or #4) or both. hCas9 was co-transfected with gRNA #3, gRNA #4, or both into L10a-GFP mESCs. We observed 39.9% GFP -cells using gRNA #3, 43.3% GFP -cells using gRNA #4, and 49.3% using both gRNAs (Fig. 2E) . We confirmed GFP knockout by microscopic imaging of replated, FACS-sorted GFP -cells (Fig. 2F) . Furthermore, western blotting confirmed loss of GFP protein expression in the sorted GFP -cells (Fig. 2G) . We genotyped GFP-clones targeted by two gRNAs by Sanger sequencing of PCR amplicons and confirmed deletion between two gRNA cut sites. Since dual gRNAs do not impair and may enhance knockout efficiency, and since paired gRNAs induces a deletion that facilitates genotyping (see below), in the following experiments we typically used two gRNAs per target gene to simplify detection of genome modification.
The frequency of off-target Cas9 activity can be reduced using a Cas9 point mutant, hCas9-D10A, which introduces single nicks rather than double strand breaks [11] [12] [13] . We tested the effectiveness of the hCas9-D10A nickase for generating gene knockouts (Fig. 2H) . When we co-transfected hCas9-D10A nickase with one gRNA #5, the efficiency of ablating GFP was low (1.72%), as expected since DNA nicking should not induce NHEJ-mediated mutagenesis. The same individual gRNA cotransfected in parallel with wild-type hCas9 yielded 43.7% GFP -cells. However, hCas9-D10A co-transfected with a second gRNA designed to introduce a nick on the opposite strand with 59 overhangs (gRNA #5 and gRNA #9, Fig. 2B ) [11] yielded 32.3% GFP -cells. While this efficiency is slightly lower than that achieved using the wild-type hCas9, this reduction is may be a worthwhile tradeoff for reduced off-target mutagenesis with hCas9-D10A.
Having defined parameters that permit efficient Cas9-mediated gene knockout in mESCs, we next targeted Smad2, MLL2, and CHD7, mutations of which have been implicated in human congenital heart disease [14] (Fig. 3A) . First, we targeted Smad2 in NKX2.5-GFP mESCs, in which the cardiomyocyte-specific NKX2.5 promoter drives GFP expression, by co-transfecting pCas9-GFP with two gRNAs for Smad2. We performed GFP FACS to enrich for cells with high Cas9-GFP expression and then clonally expanded them. We analyzed genomic DNA from clones to determine the Smad2 knockout efficiency. PCR amplification of pooled genomic DNA using primers flanking both gRNA-target sites showed that hCas9 plus two gRNAs generated the expected full length PCR product plus a smaller product, which corresponded to mutant alleles containing a deletion. Notably, the smaller PCR product was more intense than the wild-type band, suggesting highly efficient, targeted mutagenesis (Fig. 3B) . We confirmed this result by treating PCR-amplified pooled genomic DNA with surveyor nuclease, which cleaves heteroduplex DNA, on pooled genomic DNA. Compared to untreated cells, Cas9 with gRNA treated cells yielded additional nuclease cleavage products (Fig. 3C) . PCR genotyping showed that 32 out of 56 clones (57%) were homozygous mutants, 14 out of 56 (25%) were heterozygous mutants, and 10 out of 56 (18%) were wild-type ( Fig. 3D-E) . This likely underestimates the mutagenesis efficiency, since the larger PCR band may actually contain smaller indel mutations, which could occur if only one of the two gRNAs cleaved its target.
In scarless genome editing without positive selection, enrichment for transfected cells is an important step to increase the fraction of colonies that harbor a mutation of interest. We compared targeted Smad2 mutagenesis efficiency using FACSselection of GFP + cells transfected with Cas9-GFP (above) to an alternative procedure in which Cas9 expression plasmid was cotransfected with pgk-puro. 48 hours after transfection, cells underwent 48 hours of puromycin selection. We genotyped 54 independent clonal outgrowths and obtained 19 (34%) homozygous mutants, 29 (51.8%) heterozygous mutants, and 8 (14.3%) without apparent modification ( Figure 3F ). These data indicate that co-transfection with pgk-puro and transient puromycin selection or co-expression of GFP with FACS enrichment are both suitable for enrichment of transfected cells in Cas9 genome editing experiments, although FACS selection for GFP may yield a greater proportion of targeting of both alleles. We sequenced 9 clones in which both Smad2 alleles were mutated based on the PCR genotyping assay. The Sanger sequencing data showed that all of these clones did indeed have homozygous deletion of the region between the two gRNAs. We further confirmed Smad2 knockout at the protein level by performing western blotting. SMAD2 protein was indeed ablated in the clones assigned the Smad2 2/2 genotype by the PCR genotyping assay (Fig. 3G) .
We used the same knockout strategy with GFP FACS enrichment to mutate Mll2 and Chd7 in mESCs. PCR genotyping demonstrated that mESCs targeted with hCas9-GFP and two gRNAs were efficiently mutated at the Mll2 and Chd7 loci: 23 of 39 clones (59%) genotyped contained substantial homozygous Mll2 deletions (Fig. 3H-I) , and 16 of 48 clones (33%) genotyped contained substantial homozygous Chd7 deletions (Fig. 3J-K) . We confirmed reduction of Mll2 and Chd7 mRNA expression in 3 independent clones of each target locus (Fig. 3I, K ). Although these clones had confirmed gene deletions, only some had reduced transcript level, likely due to variability in nonsense-mediated decay.
These data demonstrate that the CRISPR system achieves highly efficient scarless genome editing at several different loci. Using optimized transfection conditions and FACS selection of transfected cells by co-transfected GFP fluorescence yields highly efficient mutagenesis. Use of two gRNAs permits efficient identification of mutated clones by PCR genotyping. The hCas9D10A mutant also achieves efficient mutagenesis with potentially reduced off-target activity.
Targeted DNA base changes using CRISPR Having successfully used CRISPR to knock out genes in mouse ES cells, we further evaluated the utility of CRISPR for targeted gene modification, rather than simple knockout. We assessed the efficiency of Cas9 to introduce a T.C mutation into the gene Sap130. We used nucleofection to introduce pCas9-GFP, Sap130-targeted gRNA, and donor oligo harboring the desired T.C mutation into mESCs (Fig. 4A) . We performed FACS sorting to select transfected, GFP-expressing cells, and then clonally expanded them. Conducting the surveyor nuclease assay on pooled genomic DNA demonstrated highly efficient genome modification, since nearly all of the PCR products were cleaved by the nuclease (Fig. 4B) . PCR amplification of genomic DNA followed by Sanger sequencing for 48 clones showed that 4 clones (8.3%) were homozygous for the desired T.C mutation. Of the remaining clones, 34 (70.8%) contained different sequences at the two alleles (''heterozygous''), 3 (6.3%) were wild-type (Fig. 4C) , and 7 (14.6%) had the same indel mutation on both alleles (''homozygous indel''). The frequency of homozygous indel mutants was surprising, and we confirmed this result for 2 randomly selected clones by cloning the genomic DNA PCR product and sequencing 16 independent clones. One potential reason for this observation is that the mutagenic event on one allele might be transferred to the second (e.g by inter-allelic gene conversion). Overall, our data indicate that scarless introduction of a targeted point mutation can be efficiently achieved using this approach.
Targeted DNA insertions using CRISPR
We next evaluated the ability of CRISPR to introduce an exogenous DNA sequence, such as an epitope tag, into a target locus. We already had in hand a traditional targeting vector designed to introduce FLAG and BIO [15] epitope tags onto the C-terminus of Mef2c. This targeting vector contained 1 kb and 4 kb homology arms, the 99 bp FLAG-BIO tag, and a 1.8 kb pgkNeo resistance cassette (Fig. 5A) . In a traditional gene targeting experiment without Cas9 and with G418 selection, we obtained 8 correctly targeted clones out of 192 screened mESCs (4.2%). In comparison, we transfected the targeting vector with hCas9-GFP Out of 46 clones genotyped, 9 were properly targeted (19.6%; Fig. 5A ). In comparison, omission of Cas9 yielded no correct clones out of 24 tested (P = 0.023, Fisher's exact test; Fig. 5A ). These data show that CRISPR greatly increases HDR efficiency and facilitates knockin gene modification of foreign DNA sequences up to several kilobases in length. Traditional targeting vectors have long homology regions and a positive selectable marker to overcome inefficient endogenous homologous recombination. Elimination of the selectable marker and shortening the homology arms would greatly facilitate targeting vector construction, and would obviate the need to subsequently remove the selectable marker (usually leaving a recombinase recognition sequence as a residual scar). We asked if greater HDR efficiency achieved using Cas9 would permit a simple vector consisting of the desired knockin modification flanked by 50 base pair homology regions. We generated such a simplified dsDNA donor to introduce the FLAG-BIO epitope tag into the Mef2c C-terminus (Fig. 5B) . The simplified targeting vector was co-transfected with pCas9-GFP and appropriate gRNA into mESCs. FACS-sorted, GFP + cells were clonally expanded.
Genotyping of DNA pooled from clones showed that there were two PCR bands in the Cas9 co-transfected group, with the larger amplicon arising from insertion of the FLAG-BIO tag at the Mef2c C-terminus (Fig. 5C ). Genotyping of 22 individual clones showed that 8 (36.3%) contained the Flagbio insertion. We validated the function of the inserted FLAG-BIO tag by transfecting two genotype positive clones with a BirA expression plasmid. BirA recognizes the BIO peptide and biotinylates it [15] . To test the successful tagging and biotinylation of Mef2c, ESC lysates were incubated with streptavidin beads, and material bound to the beads was immunoblotted with anti-FLAG antibody. This showed that a FLAG-tagged protein with appropriate molecular weight for MEF2C was efficiently pulled down on the SA beads (Fig. 5D) , confirming the functionality of the knockin allele. A 99 bp, the FLAG-BIO epitope tag is still relatively small. To investigate the ability of Cas9 and a simplified targeting vector containing only 50 bp homology arms to knockin a larger foreign DNA fragment, we attempted to fuse GFP to MEF2C. This targeting vector contained the GFP open reading frame (720 bp) flanked by the same 50 bp homology arms as used for introduction of FLAG-BIO (Fig. 5E) . We co-transfected this targeting vector with pCas9-GFP and Mef2c gRNA into mESCs. GFP + cells were isolated by FACS and clonally expanded. Pooled DNA from resultant clones was positive for a diagnostic PCR product (Fig. 5F ). Genotyping 46 individual clones identified 2 positive clones (4.3%). Embryoid body differentiation of one of the positive clones induced GFP fluorescence in regions of the embryoid body, suggesting that the GFP tag was functional (Fig. 5G) . Sequencing of RTPCR product confirmed the desired fusion of GFP cDNA to Mef2c. These data show that HDR driven by Cas9 can be used for targeted insertion of a fragment several hundreds of base pairs long using a simple targeting vector with only 50 bp homology arms and no selectable marker. To see if another locus can be effectively modified by this strategy, we targeted Oct4, a transcription factor expressed in mESCs. Oct4 50 -GFP donor, containing 50 bp homology arms, gRNA and Cas9 were co-transfected into mESCs. In this case, it was not possible to enrich for transfected cells by FACS. After 10 days of ESC culture, FACS analysis showed that this treatment generated 0.7% GFP + cells (Fig. 6A ). Since this experiment did not enrich for transfected cells, the frequency of desired targeting amongst transfected cells is likely more then 5-fold higher (assuming a transfection efficiency of 20%). Genotype positive clone #38 stably expressed OCT4-GFP, as confirmed by fluorescent imaging and western blotting (Fig. 6B-C) .
To determine if longer homology arms could increase efficiency of HR-mediated knockin, we tested 200 bp homology arms, as arms of this length can easily be synthesized as oligonucleotides. Using Gibson assembly, we generated an Oct4 200 -GFP donor, containing 200 bp homology arms. We introduced this construct into mESCs with Cas9 and appropriate gRNA. After 10 days of ESC culture, FACS analysis showed that this treatment generated 5.8% GFP + cells (Fig. 6A) . Genotyping of GFP + clones confirmed appropriate knockin at the Oct4 locus (Fig. 6D ). These data show that increasing homology arm length from 50 to 200 bp increased targeting efficiency by more than 9-fold.
Discussion
Scarless, targeted genome modification using designer sitedirected nucleases such as CRISPR/Cas9 is a game changing technology. Here we optimized several aspects of this approach to enhance its efficiency. In a system where there is no selection for the desired product, the most important step is to achieve efficient transfection and then to enrich for transfected cells. Nucleofection and LF3000 are good transfection options for murine ESCs. Enrichment for transfected cells can be achieved by FACS sorting for GFP co-expressed from the hCas9-GFP plasmid, or cotransfection with a puromycin resistance marker followed by transient puromycin selection [11] . We found that both enrich- ment strategies were effective, although GFP FACS selection may yield a higher fraction of mutants with targeting of both alleles. On the other hand, one advantange of transient puromyocin selection is that cells do not need to leave the controlled environment of the cell culture room and be processed on a FACS machine, with attendant risks of mycoplasma or bacterial contamination.
It is important to consider downstream genotyping when designing a gene targeting strategy. Small indel mutations introduced by NHEJ using a single gRNA can be difficult to detect without DNA sequencing. Sanger sequencing can become expensive when many clones need to be screened. Moreover standard Sanger sequencing data can be difficult to interpret because indel mutations cause chromatogram phase shifts, so that it can be difficult to distinguish homozygous and heterozygous mutants [16] . We showed that dual gRNAs do not reduce (and may marginally enhance) targeting efficiency and simplify genotyping by causing more extensive deletions that are easily detected by PCR genotyping. This strategy can also be used to excise regions of DNA, such as transcriptional regulatory sequences. One downside to the use of paired gRNAs for gene knockout is that use of two gRNAs might increase the chance of off-target genome modification. We showed that one gRNA plus a DNA donor containing a stop codon enhances functional gene knockout. Addition or removal of restriction sites in addition to a stop codon or frameshift mutation in an HDR donor is an alternative strategy to facilitate downstream genotyping [17] , although HR-dependent targeting tends to be several fold less efficient than NHEJ.
It has been suggested that a ''dual nick'' strategy, in which two gRNAs direct the Cas9D10A single strand nickase activity to nearby sites to yield an effective double strand break, will be a effective means to minimize off-target mutagenesis [11, 13] , because the two gRNAs will rarely yield nearby nicks outside of the target locus. Our data support this idea, since mutagenesis by the nickase plus a single gRNA occurred at a low (but detectable) frequency. Paired gRNAs that induced nearby nicks stimulated mutagenesis by approximately 20-fold. Thus, efficient mutagenesis with minimal off-target activity could best be achieved using the Cas9D10A nickase and paired gRNAs. However, genotyping of the resulting small indel mutations will be more labor intensive and costly.
CRISPR/Cas9 greatly facilitates targeted genome modification and introduction of new DNA sequences at a target locus. This technology will facilitate generation of novel reagents, such as proteins labeled with affinity or fluorescent tags. We explored the variables that influence efficient introduction of new DNA sequences at a target locus. The size of the insert was an important variable, with larger inserts reducing the efficiency of genome modification. For instance, at the Mef2c locus, changing the insert length from 99 bp to 720 bp reduced modification frequency 9-fold (36.3% to 4.3%). On the other hand, increasing the homology arm size increased modification frequency: at the Oct4 locus, increasing the homology arm size from 50 bp to 200 bp increased the frequency of inserting a 720 bp fragment by 8-fold (0.7% to 5.8%; note these are the frequencies of modification of all cells, not transfected cells). Using TALENs to induce HDR modification of a single nucleotide, Hendel et al.
showed that 400 bp homology arms improved HDR about 3-fold compared to 200 bp, while 800 bp was equivalent to 400 bp [18] . Increasing homology arm size can compensate for increased insert size. For example, at the Mef2c locus, an 2135 bp fragment was introduced with 19.6% efficiency with 1 kb and 4 kb homology arms. Using Gibson assembly [8] , 200-400 bp homology arms can be added to an insert with ease. Therefore, we recommend use of homology arms of this length for larger DNA insertions. For shorter inserts (,100 bp), 50 bp homology arms are sufficient, so that the entire targeting construct can be synthesized as an oligonucleotide.
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